Mesoblast Limited (MEOBF)

Market Cap	2.21B +14.7%
Revenue (ttm)	65.38M +1,053.2%
Net Income	-94.37M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,125
Open	1.300
Previous Close	n/a
Day's Range	1.300 - 1.890
52-Week Range	1.300 - 2.590
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 81
• Stock Exchange: OTCMKTS
• Ticker Symbol: MEOBF

Financial Performance

In fiscal year 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 11, 2026

Data Sources Report a data error